New product boost for Duopharma

RHB said it believes that Duopharma’s financial performance will continue to be supported by robust drug procurement.

PETALING JAYA: Duopharma Biotech Bhd is expected to have a solid year in 2023, driven by higher insulin contracts, new products and reinvestment allowance incentives.

All of this is anticipated to help mitigate cost pressures from rising overnight policy rates, electricity tariffs and labour costs, said TA Research.